XENE
Xenon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$39.75
−30.69%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$44.00
From 52W high−43.98%
Volume17.83M
Market cap$3.85B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$44.00
From 52W high
−43.98%
Volume
17.83M
Market cap
$3.85B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.0x
P/E (TTM)
—
RSI (14)
13.9
MomentumView details →
1D Return
−30.69%
YTD Return
−11.16%
SummaryUpdated Jun 1, 2026
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is a clinical-stage biopharmaceutical company founded in 1996 and headquartered in Burnaby, Canada. The company specializes in developing neurological therapeutics by targeting ion channels, particularly potassium and sodium channels in the brain. Xenon has built its expertise around understanding the genetic basis of neurological disorders and translating these insights into targeted drug therapies. The company went public in 2014 and has since advanced multiple drug candidates through clinical trials, with its lead program <b>azetukalner</b> (XEN1101) currently in Phase 3 trials for epilepsy and depression.
Similar companies
Latest newsMore news →
Xenon Pharmaceuticals temporarily paused enrollment of new patients in its clinical studies of an experimental drug for major depression and bipolar disorder following reports of mental and nervous system-related side effects.3d agoXenon Pharmaceuticals submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner for the treatment of focal seizures.3d ago